Stable angina
Stable angina is the most common type of angina, the chest pain or discomfort that comes when the heart muscle does not get enough blood. A US government patient page says it comes on when the heart works harder than usual, follows a regular pattern, and usually eases with rest and medicines. MeSH describes it as lasting, repeatable chest discomfort that physical effort usually brings on and that fades when the effort stops.
Also called Angina, Stable
- Condition
- In this atlas
Overview
Technical summary
MeSH D060050, last updated 2017-06-20; the description rests on its scope note. The patient page is the MedlinePlus angina summary, which calls angina a symptom of coronary artery disease. The plan for this record also named chronic coronary syndrome; no source read states that the two terms are equal, so the record uses the name stable angina.
Recognition
A US government patient page says angina may feel like pressure or a squeezing pain in the chest, may feel like indigestion, and may also be felt in the shoulders, arms, neck, jaw or back.
Burden
No burden claims are published.
Claims and evidence
No claims are published for this condition yet.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Amlodipine
Applies to Recipient not specified People for whom the US label of amlodipine (Norvasc) lists an indication: hypertension, chronic stable angina, vasospastic angina, documented coronary artery disease
Population, setting and follow-up
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of NORVASC (amlodipine besylate), in the Viatris Specialty LLC version dated 2023-02-15 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure; for the symptomatic treatment of chronic stable angina; for the treatment of confirmed or suspected vasospastic angina; and, in patients with recently documented coronary artery disease by angiography and without heart failure or an ejection fraction under 40%, to reduce the risk of hospitalization for angina and of a coronary revascularization procedure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Calcium channel blockers
Applies to Recipient not specified People with hypertension or coronary artery disease, as described in the US label of a calcium channel blocker
Population, setting and follow-up
- Patients described in the indications section of the label: patients with hypertension, and patients with chronic stable angina, vasospastic angina, or angiographically documented coronary artery disease without heart failure or an ejection fraction under 40%.
- Prescription medicine, as described in the US label
- United States (US drug label)
- Not stated in the passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of NORVASC (amlodipine besylate tablets, Viatris Specialty LLC, application NDA019787; the version dated 2023-02-15 in openFDA) calls the medicine a calcium channel blocker that may be used on its own or in combination with other antihypertensive and antianginal agents. It lists the treatment of hypertension, and coronary artery disease in three forms: chronic stable angina, vasospastic angina, and angiographically documented coronary artery disease in patients without heart failure or an ejection fraction under 40%. MeSH describes the class as drugs that act by selective inhibition of calcium influx through cellular membranes.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The medicine is a dihydropyridine, so the label does not stand for every calcium channel blocker. The label text read states no age range. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Diltiazem
Applies to Recipient not specified People for whom the US label of diltiazem (Cardizem) lists an indication: chronic stable angina, angina due to coronary artery spasm
Population, setting and follow-up
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of CARDIZEM (diltiazem hydrochloride), in the Bausch Health US LLC version dated 2025-04-30 in openFDA, lists the medicine for the management of chronic stable angina and angina due to coronary artery spasm.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Nifedipine
Applies to Recipient not specified People for whom the US label of nifedipine extended-release tablets lists an indication: vasospastic angina, chronic stable angina
Population, setting and follow-up
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of nifedipine extended-release tablets, in the Upsher-Smith Laboratories, LLC version dated 2026-01-19 in openFDA, lists the medicine for the management of vasospastic angina, and for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers or organic nitrates, or who cannot tolerate those agents.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Verapamil
Applies to Recipient not specified People for whom the US label of verapamil hydrochloride tablets lists an indication: angina, atrial flutter or fibrillation, supraventricular tachycardia, hypertension
Population, setting and follow-up
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of verapamil hydrochloride tablets, in the Actavis Pharma, Inc. version dated 2024-01-30 in openFDA, lists the medicine for angina (angina at rest, including vasospastic and unstable angina, and chronic stable angina); for arrhythmias (control of ventricular rate at rest and during stress, in association with digitalis, in patients with chronic atrial flutter or atrial fibrillation, and prophylaxis of repetitive paroxysmal supraventricular tachycardia); and for the treatment of hypertension, to lower blood pressure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 58
Record details
- Record id
cardio:stable-angina- Content hash
1ab942bce8c6f85a2c7be9dd99b2a1659db1cd7c6f3f25213892bd87a0857cc6